SAN DIEGO, Sept. 22, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, 'Sorrento' or 'Company'), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, announced the consummation on September 21, 2023, of the previously announced sale to Scilex Holding Company (Nasdaq: SCLX, 'Scilex') of certain securities that Sorrento held in Scilex..

2023年9月22日，圣地亚哥/PRNewswire/-Sorrento Therapeutics，Inc。（OTC:SRNEQ，'Sorrento'或'公司'），一家致力于开发挽救生命的治疗癌症的生物制药公司，顽固性疼痛和传染病，于2023年9月21日宣布完成，之前宣布出售给Scilex控股公司（纳斯达克股票代码：SCLX，'Scilex'）的索伦托持有在Scilex的某些证券。。

Pursuant to that certain Stock Purchase Agreement entered into on September 21, 2023, between Scilex and Sorrento, Scilex, through its wholly-owned subsidiary, acquired (i) all of the shares of Scilex common stock owned by Sorrento (other than such shares held in abeyance by Sorrento on behalf of certain warrant holders of Sorrento), (ii) all of the shares of Scilex preferred stock owned by Sorrento, and (iii) all of the warrants for the purchase of shares of Scilex common stock owned by Sorrento (collectively, the 'Securities Transfer') for aggregate consideration consisting of: (i) $110 million (comprised of cash payments of $10 million (in the aggregate) and the assumption by Scilex of the approximately $100 million senior secured term loan facility provided by Oramed Pharmaceuticals Inc.

根据Scilex与Sorrento于2023年9月21日签订的某些股票购买协议，Scilex通过其国有子公司收购（i）Sorrento拥有的Scilex普通股的所有股份（Sorrento代表Sorrento的某些认股权证持有人暂时搁置的股份除外），（ii）索伦托拥有的Scilex优先股的所有股份，（iii）购买索伦托拥有的Scilex普通股股份的所有认股权证（统称为「证券转让」）以供综合考虑，包括：（i）1.1亿美元（包括现金支付1000万美元）（总计）以及Scilex对Oramed Pharmaceuticals Inc.提供的约1亿美元高级担保期贷款设施的假设。

(Nasdaq: ORMP, 'Oramed') to Sorrento ); plus (ii) the assumption by Scilex of certain legal fees and expenses of Sorrento in the amount of approximately $12.25 million; plus (iii) a credit bid of all amounts owed to Scilex under the junior secured debtor-in-possession financing facility provided by Scilex to Sorrento.

（纳斯达克股票代码：ORMP，'Oramed'）到索伦托）；加上（ii）Scilex假设Sorrento的某些法律费用和费用约为1225万美元；加上（iii）根据Scilex向Sorrento提供的初级担保债务持有融资设施，向Scilex支付的所有金额的信用投标。

As a result of the Securities Transfer, the Company no longer has a controlling interest over Scilex and Scilex ceased to be a majority-owned subsidiary of Sorrento. Consequently, we expect Scilex will be deconsolidated from the Company's financial statements prospectively and will be presented as discontinued operations..

由于证券转让，本公司不再对Scilex拥有控制权，并且Scilex不再是Sorrento的多数子公司。因此，我们预计Scilex将从公司的财务报表中前瞻性地整合，并将作为已停产的业务呈现。。

Additionally, upon the closing of the Securities Transfer, Sorrento and Oramed mutually terminated that certain Stock Purchase Agreement (as amended, the 'Oramed SPA'), dated as of August 7, 2023, between Oramed and Sorrento for the sale of Sorrento's equity interests in Scilex to Oramed, which termination includes a release of claims by each of the parties relating to the Oramed SPA..

此外，在证券转让结束时，Sorrento和Oramed相互终止了截至2023年8月7日Oramed和Sorrento之间的某些股票购买协议（经修订，“Oramed SPA”），用于出售Sorrento的股权。在Scilex对Oramed的权益，终止包括各方释放与Oramed SPA有关的权利要求。。

About Sorrento Therapeutics, Inc.

关于索伦托治疗公司。

Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as next-generation tyrosine kinase inhibitors ('TKIs'), fully human antibodies ('G-MAB™ library'), immuno-cellular therapies ('DAR-T™'), antibody-drug conjugates ('ADCs'), and oncolytic virus ('Seprehvec™').

Sorrento是一家临床和商业阶段的生物制药公司，开发治疗癌症，疼痛（非阿片类药物治疗），自身免疫性疾病和新型冠状病毒肺炎的新疗法。索伦托通过其广泛的免疫肿瘤学平台，包括下一代酪氨酸激酶抑制剂（TKIs）、全人抗体（G-MAB）等关键资产，实现了索伦托多模式、多管齐下的抗癌治疗™ 图书馆），免疫细胞疗法（'DAR-T™'), 抗体药物偶联物（'ADC'）和溶瘤病毒（'Seprehvec™').

Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including STI-1558 and COVI-MSC™; and diagnostic test solutions, including COVIMARK™..

索伦托还在开发针对冠状病毒的潜在抗病毒疗法和疫苗，包括STI-1558和COVI-MSC™; 和诊断测试解决方案，包括COVIMARK™..

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a TRPV1 agonist, non-opioid pain management small molecule, resiniferatoxin ('RTX'). RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients..

Sorrento对患者生命增强疗法的承诺也体现在我们努力推进TRPV1激动剂，非阿片类疼痛管理小分子树脂毒素（'RTX'）。RTX已被批准用于与癌症相关的顽固性疼痛的II期试验和骨关节炎患者的II期试验。。

For more information visit www.sorrentotherapeutics.com.

欲了解更多信息，请访问www.sorrentotherapeutics.com。

Forward-Looking Statements

前瞻性声明

This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Sorrento and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

本新闻稿以及在任何演讲或会议上就本新闻稿中讨论的事项作出的任何陈述，均包含根据1995年“私人证券诉讼改革法”第21E条安全港规定与Sorrento及其子公司有关的前瞻性陈述，并可能受到可能导致实际结果的风险和不确定性的影响与预期的大不相同。

Forward-looking statements generally are accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook,' and similar expressions. Forward-looking statements include statements regarding the Securities Transfer and the anticipated accounting treatment resulting from the Securities Transfer.

前瞻性陈述通常伴随着诸如“相信”，“可能”，“将会”，“估计”，“继续”，“预期”，“打算”，“期望”，“应该”，“将会”，“计划“，”预测“，”潜力“，”似乎“，”寻求“，”未来“，”展望“和类似的表达方式。前瞻性陈述包括关于证券转让的陈述以及证券转让带来的预期会计处理。

.

.

Risks and uncertainties that could cause Sorrento's actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to risks associated with the ability of the Company to use such proceeds efficiently in support of its business; the Company's ability to obtain exit financing and to pursue a plan of reorganization to exit its chapter 11 bankruptcy; and those factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent Quarterly Reports on Form 10-Q filed with the SEC in each case under the heading 'Risk Factors,' and other documents of the Company filed, or to be filed, with the SEC.

可能导致索伦托实际结果与我们的前瞻性声明中所表达的实质性和不利影响的风险和不确定性包括但不限于与公司有效使用此类收益以支持其业务的能力相关的风险；公司获得退出融资和寻求重组计划以退出第11章破产的能力；以及本公司关于2022年12月31日结束的年度10-K年度报告中讨论的那些因素，以及随后在每种情况下以“风险因素”标题向SEC提交的表格10-Q的季度报告以及其他文件本公司已向SEC提交或将要提交。

If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently does not know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements.

如果风险实现或假设证明不正确，实际结果可能与这些前瞻性陈述所暗示的结果有很大差异。本公司目前不知道或本公司目前认为不重要的其他风险也可能导致实际结果与前瞻性声明中包含的结果不同。

Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, and Sorrento undertakes no obligation to update any forward-looking statement in this press release except as may be required by law..

提醒投资者不要过分依赖这些仅在本新闻稿发布之日才发表的前瞻性声明，Sorrento不承担更新本新闻稿中任何前瞻性声明的义务，除非可能需要法律。。

Contacts:

联络：

For Sorrento Therapeutics, Inc.

索伦托治疗公司。

Media Contact

媒体联系

The Levinson Group212-202-2754Email: [email protected]Website: www.sorrentotherapeutics.com

莱文森集团212-202-2754电子邮件：[电子邮件保护]网站：www.sorrentotherapeutics.com

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

Sorrento®和Sorrento徽标是Sorrento Therapeutics，Inc。的注册商标。

G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVI-MSC™, COVIMARK™, Fujovee™ and Ovydso™ are trademarks of Sorrento Therapeutics, Inc.

G-MAB的™, DAR-T™, Seprehvec公司™, 索福萨™, COVI-MSC™, COVIMARK公司™, Fujovee™ 和Ovydso™ 是Sorrento Therapeutics，Inc。的商标。

All other trademarks are the property of their respective owners.

所有其他商标均为其各自所有者的财产。

SOURCE Sorrento Therapeutics, Inc.

来源索伦托治疗公司。